Cancer Research in Switzerland - Krebsliga Schweiz

More documents

Recommendations

Info

200 Findings of the INHANCE study also suggested that the risks of HNC for beer and liquor are comparable. A greater than multiplicative effect between ever tobacco and alcohol use was observed for HNC risk. The population attributable risk for tobacco or alcohol was 72 % for HNC, of which 4 % was due to alcohol alone, 33 % was due to tobacco alone and 35 % was due to tobacco and alcohol combined. Quitting tobacco smoking resulted in a HNC risk reduction in the short term. For alcohol use, a beneficial effect on the risk of HNC was only observed after ≥ 20 years of quitting. Additional and more detailed collaborative analyses within the INHANCE consortium were conducted on: a) total exposure and exposure rate effects of alcohol and smoking and risk of HNC; b) cessation of alcohol drinking, tobacco smoking and the reversal of HNC; and c) interaction between tobacco and alcohol use and risk of HNC. The major results of the research are published to increase the project impact on various aspects of public health and prevention and, in particular, the assessment of the individual risks and their public health implications. Project coordinator Prof. Dr Fabio Levi Unité d’épidémiologie du cancer et Registres vaudois et neuchâtelois des tumeurs Institut universitaire de médecine sociale et préventive Centre hospitalier universitaire vaudois (CHUV) Chemin des Falaises 1 CH-1011 Lausanne Phone +41 (0)21 314 73 11 fabio.levi@chuv.ch Zwahlen Marcel | Risk of childhood leukemia varies little by familial socio-economic status – while survival time after a brain tumor diagnosis varied considerably by familial socio-economic status (OCS 1869-02-2006) Research on origins and determinants of childhood cancer is still important, because the aetiology of childhood cancer remains poorly understood. Whether diseases are occurring more frequently in persons with lower socioeconomic status (SES) is a question that is regularly asked. In a nationwide study of the SCCR and the Swiss National Cohort (SNC) using data of the 1990 and 2000 census, we examined, first, the association of SES level and the risk of leukaemia and, second, the association of SES level and mortality in childhood cancer patients. In the case-control study part we found weak evidence for a positive association of childhood leukaemia with higher education of mother but no evidence of an association with other family indicators of SES. The odds ratio for leukaemia and SES, comparing the highest SES category with the lowest SES category, was 1.37 (1.00–1.89) for mother’s education, 0.95 (95 % CI: 0.71–1.26) for father’s education and 0.96 (95 % CI: 0.74–1.25) for number of rooms per person. This might imply that childhood leukaemia risk is positively associated with a specific exposure linked to higher education of the mother. When analyzing survival after a cancer diagnosis, SES differentials were virtually absent for leukaemia patients but existed for other childhood cancers, especially for patients with a tumour of the central nervous system. Mortality was lower in higher SES groups compared to lower SES groups. Depending on the SES measure used, hazard ratios ranged from 0.48 (95 % CI: 0.28–0.81) to 0.71 (95 % CI: 0.44–1.15) when comparing the highest with the lowest SES group. This might imply an association of SES with access to health care and treatment decisions, which in turn would be associated with treatment outcome. To improve health conditions and care in all socioeconomic groups in high-income countries with mandatory health insurance like Switzerland, it is important to understand the causes of childhood cancer and the mechanisms that are responsible for differences in survival after a cancer diagnosis in children. Project coordinator Prof. Dr. Marcel Zwahlen Institut für Sozial- und Präventivmedizin Universität Bern Finkenhubelweg 11 CH-3000 Bern Phone +41 (0)31 631 35 11 zwahlen@ispm.unibe.ch
Epidemiological research List of approved research projects in 2009/2010 Total funds allocated: CHF 2,134,950.– Bordoni Andrea | KFS 02668-08-2010 | CHF 232,700.– Registro cantonale dei tumori, Istituto cantonale di patologia (ICP), Locarno Indicators of quality of cancer care in Southern Switzerland Bouchardy Christine | KFS 02544-02-2010 | CHF 315,900.– Registre genevois des tumeurs, Institut national pour l’épidémiologie et l’enregistrement du cancer (NICER), Genève Impact of genetic factors in breast cancer occurrence, treatment and outcome using populationbased data from the first Familial breast cancer registry in Switzerland Clough-Gorr Kerri | KFS 02553-02-2010 | CHF 381,300.– NICER, c/o Institut für Sozial- und Präventivmedizin, Universität Zürich, Zürich The Swiss National Cohort (SNC) and the National Institute for Cancer Epidemiology and Registration (NICER) – cancer epidemiology study, 1990 – 2008 Keiser Olivia | KFS 02478-08-2009 | CHF 225,700.– Institut für Sozial- und Präventivmedizin, Universität Bern, Bern Changes and determinants of cancer patterns among persons infected with HIV in the era of combined antiretroviral therapy in Switzerland Levi Fabio | KFS 02437-08-2009 | CHF 270,000.– Unité d’épidémiologie du cancer et Registres vaudois et neuchâtelois des tumeurs, Institut universitaire de médecine sociale et préventive, Centre hospitalier universitaire vaudois (CHUV), Lausanne Modelling, interpretation and forecasting of cancer mortality in Europe Michel Gisela | KLS 02631-08-2010 | CHF 283,300.– Institut für Sozial- und Präventivmedizin, Universität Bern, Bern Effectiveness of transition to adult care after childhood cancer Mullis Primus-Eugen | KLS 02586-02-2010 | CHF 184,300.– Abteilung pädiatrische Endokrinologie, Diabetologie und Stoffwechsel, Universitätsklinik für Kinderheilkunde, Inselspital, Bern Risk of cancer and longterm mortality in children treated with growth hormone: Swiss participation in the EU FP7 project “Safety and Appropriateness of Growth Hormone Treatment in Europe (SAGhE)” Thürlimann Beat | KFS 02474-08-2009 | CHF 25,900.– Brustzentrum, Kantonsspital St. Gallen, St. Gallen Management of breast cancer in the elderly in Switzerland Vounatsou Penelope | KLS 02393-02-2009 | CHF 215,850.– Biostatistics and Computational Sciences Unit, Departement für Epidemiologie und Gesundheitswesen, Schweizerisches Tropen- und Public Health-Institut, Basel Spatiotemporal patterns and forecasting of gender specific lung and other tobaccorelated cancer mortality and morbidity rates in Switzerland 201
Page 1 and 2:
Cancer Research in Switzerland A pu
Page 3 and 4:
Cancer Research in Switzerland
Page 5 and 6:
Basic biomedical research 55 Cancer
Page 7 and 8:
policy work and was in charge of de
Page 9 and 10:
The main focus of the research fund
Page 11 and 12:
gramme research funding decreased b
Page 13 and 14:
Table 2 Distribution of funds for i
Page 15 and 16:
Funding patient-centred research Pa
Page 17 and 18:
value was not clearly discernible.
Page 19 and 20:
New organization of the Foundation
Page 21 and 22:
The board of the Foundation Cancer
Page 23 and 24:
The president of the Scientific Com
Page 25 and 26:
Prof. Martin Pruschy, PhD Departmen
Page 27 and 28:
Swartz wants to find out how tumour
Page 29 and 30:
The scientific and medical research
Page 31 and 32:
3. The original order/sequence of t
Page 33 and 34:
As a federation, the Cancer League
Page 35 and 36:
List of funded research projects, i
Page 37 and 38:
Zippelius Alfred | 2009: CHF 100,00
Page 39 and 40:
Kridel Robert | 2010: CHF 100,000.-
Page 41 and 42:
Thurgau Cancer League Biotechnologi
Page 43 and 44:
Weller Michael | 2010: CHF 65,828.-
Page 45 and 46:
manageable funding of individual pr
Page 47 and 48:
enhances breast cancer cell motilit
Page 49 and 50:
Rüegg Curzio et al. | Tumor-mediat
Page 51 and 52:
International Clinical Cancer Resea
Page 53 and 54:
in PHIV were shown for Hodgkin’s
Page 55:
Zucca Emanuele et al. | Internation
Page 58 and 59:
56 “hierarchical structure” of
Page 60 and 61:
58 the attempt should be made to st
Page 62 and 63:
60 Gönczy Pierre | KLS 0202402
Page 64 and 65:
62 Romero Pedro | OCS 020110220
Page 66 and 67:
64 Beermann Friedrich | In vivo scr
Page 68 and 69:
66 Christofori Gerhard | Podoplanin
Page 70 and 71:
68 Frei Christian | The function of
Page 72 and 73:
70 cell, this novel mechanism serve
Page 74 and 75:
72 Results The induction of viral p
Page 76 and 77:
74 Hübscher Ulrich | Repair of oxi
Page 78 and 79:
76 Methods and experimental approac
Page 80 and 81:
78 of cMyc and/or NMyc and demo
Page 82 and 83:
80 In summary, this work improves o
Page 84 and 85:
82 Pruschy Martin | Microtubule int
Page 86 and 87:
84 Renner Christoph | Selective inh
Page 88 and 89:
86 Goal Here we build on these obse
Page 90 and 91:
88 by TDG prevents efficient downst
Page 92 and 93:
90 To address these questions, we a
Page 94 and 95:
92 Translational relevance The resu
Page 96 and 97:
94 Grünberg Jürgen | KFS 025460
Page 98 and 99:
96 Tschan Mario P. | KFS 0248608
Page 100 and 101:
98 Boyman Onur | Preclinical testin
Page 102 and 103:
100 Constam Daniel | Role of activi
Page 104 and 105:
102 this study we will examine the
Page 106 and 107:
104 Janscak Pavel | Study of the ro
Page 108 and 109:
106 Müller Anne | The molecular pa
Page 110 and 111:
108 Radtke Freddy | The role of Not
Page 112 and 113:
110 Schär Primo | DNA repair, epig
Page 114 and 115:
112 In this project we will investi
Page 116 and 117:
114
Page 118 and 119:
116 and Research). Other financial
Page 120 and 121:
118 be totally unaffordable for aca
Page 122 and 123:
120 Clinical research List of compl
Page 124 and 125:
122 Hunger Robert E. | OCS 02262-08
Page 126 and 127:
124 Clinical research Presentation
Page 128 and 129:
126 Benhattar Jean | Identification
Page 130 and 131:
128 Bertoni Francesco | Genome-wide
Page 132 and 133:
130 Interpretation ESA treatment in
Page 134 and 135:
132 Our results could pave the way
Page 136 and 137:
134 new drugs that specifically tar
Page 138 and 139:
136 slides in two different concent
Page 140 and 141:
138 Conclusions A strong network of
Page 142 and 143:
140 tions introduced to ARE motifs
Page 144 and 145:
142 Müller Beatrice U. | The maste
Page 146 and 147:
144 A novel method was developed fo
Page 148 and 149:
146 (SAKK 35-98) the Swiss Group fo
Page 150 and 151:
148 Timmermann Beate | Prospective
Page 152 and 153: 150 recurrence of the disease, we a
Page 154 and 155: 152 Zucca Emanuele | A prospective
Page 156 and 157: 154 Heinimann Karl | KFS 02489-08-2
Page 158 and 159: 156 Riggi Nicolò | BIL KFS 02717-0
Page 160 and 161: 158 activity at the single cell lev
Page 162 and 163: 160 Our research projects aim at un
Page 164 and 165: 162 Körner Meike | In vitro evalua
Page 166 and 167: 164 Nadal David | Is endemic Burkit
Page 168 and 169: 166 (> 50.000/patient). For their a
Page 170 and 171: 168 Zeller Rolf | Functional analys
Page 172 and 173: 170
Page 174 and 175: 172 area of health services researc
Page 176 and 177: 174 The financing of palliative car
Page 178 and 179: 176 National Strategy for Palliativ
Page 180 and 181: 178 Psychosocial research List of c
Page 182 and 183: 180 Within the patient group, level
Page 184 and 185: 182 Further, the results suggest th
Page 186 and 187: 184 It is in this context that the
Page 188 and 189: 186 Recommendation Female spouses o
Page 190 and 191: 188 Psychosocial research Presentat
Page 192 and 193: 190 rates communication skills rema
Page 195 and 196: Epidemiological research Epidemiolo
Page 197 and 198: data from cancer registries. In the
Page 199 and 200: The importance of cancer registries
Page 201: Ess Silvia | Patterns of care and s
Page 205 and 206: Impact This work will serve as the
Page 207 and 208: Thürlimann Beat | Management of br
show all

Cancer Research in Switzerland - Krebsliga Schweiz

Create successful ePaper yourself

Delete template?

Save as template?